# Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors

> **NCT06933524** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Autotelicbio** · enrollment: 24 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** ATB-320

## Key facts

- **NCT ID:** NCT06933524
- **Lead sponsor:** Autotelicbio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2028-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06933524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06933524, "Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06933524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*